Objective
About 10-15% of the primary hip and knee arthroplasties have to be revised after surgery. A special case of loosening of implants is the low-grade-infection, which is mostly not recognized and not treated adequately and leads to further revision surgeries and immense impact for the patient. Established markers all failed in the past, in contrast elevated calprotectin and S100A12 levels show a high correlation to low-grade-infections. Immundiagnostik AG developed its own robust smartphone-application based point-of-care assay for measuring calprotectin quantitatively and rapidly without any laboratory. Extending this concept to a calprotectin and S100A12 duplex text low-grade-infections in joint replacement can be detected within minutes for the first time ever. This method will replace time consuming laboratory testing and will help the surgeon to decide in the operation theatre if a two-stage-revision is indicated. Thus health and quality of life for patients is improved and costs for and rate of revision surgery could be reduced significantly. The market size for the new assay and app will be over 60 million Euro in a year. Users of the new diagnosis by will be clinicians in endoprosthesis centres. The innovation will be a quantitative two parameter rapid assay and a smartphone-app as a reader. Two-stage-revision surgery of endoprosthesis as a result of low-grade-infection is a European and worldwide burden. The problem can only be solved in an European consortium to ensure access to European opinion leaders in arthroplasties and to European markets and therefore broad dissemination and exploitation of the project results. Within the feasibility study (phase 1) the following work is intended: Establishing the smart low grade infection assay, patent application, market survey, setup of a multicentre clinical study, preparation of a business plan. Within the project (phase 2), the assay and app will be validated in a large European clinical study.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine surgery surgical procedures
- medical and health sciences medical biotechnology implants
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
64625 Bensheim
Germany
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.